|
|
 |
|
Viewing report
|
|
|
|
Licensing in Antibacterial R&D - Filling the Gaps
Datamonitor, March 2003, Pages: 31
Introduction:
Increasing drug-resistance, alongside growing competition and increasing costs of discovery, is decreasing the incentive to invest in novel antibacterial product development. As such, the R&D pipelines of many key companies are currently relatively weak. In order to maintain future market share, leading companies will need to seek innovation through licensure and partnership.
Scope:
- Analysis of the key drivers and resistors of licensing deals and partnership in antibacterial R&D.
- Overview of licensing activity in the antibacterial market, with particular emphasis on the leading five companies
- Current and projected future antibacterial portfolio reliance on licensed products
Report Highlights:
Patent expiries and drug resistance will lead to decreased revenues from current antibacterial products. The lack of promising in-house R&D projects means that licensing is the only option for many key players looking to maintain market share
Large pharmaceutical companies generally operate across multiple therapy areas, with antibacterial revenue forming only a small component of total ethical sales. Licensing offers a lower risk strategy for maintaining franchise sales, particularly where resource allocation to antibacterial R&D is limited.
Companies reliant on licensed products will generally demonstrate greater antibacterial growth to 2011. Aventis’ portfolio sales, however, will demonstrate the greatest increase, demonstrating the strength of its in-house resources.
Reasons to Purchase:
- Understand the key drivers and resistors of R&D licensing in antibacterials.
- Identify companies heavily reliant on licensed products in 2002 and 2011.
- Determine which players will need to in-license compounds in order to maintain market share.
Customers who bought this item also bought
Antibacterial: Drug Licensing Opportunities, 2002
Overcoming Challenges in Antibacterial Drug Discovery and Development
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Stakeholder Insight: The Hospital Antibacterial Market - Specialist Products Drive Market Growth
The 2009-2014 World Outlook for Antibacterial and Antiseptic Pharmaceuticals
The 2009-2014 Outlook for Antibacterial and Antiseptic Pharmaceuticals in Greater China
The 2009-2014 Outlook for Antibacterial and Antiseptic Pharmaceuticals in Japan
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market
The 2009 Report on Antibacterial and Antiseptic Pharmaceuticals: World Market Segmentation by City
Strategic Perspectives: The Hospital Antibacterial Market - Defining a Sector Specific Strategy
Antibacterial Market Survey: Analyses and Forecasts…Technology, Sales and Company Profiles
|
|
|
|
